Skip to content

Study · Randomized controlled trial · n = 25 · 2009

3 results

Novel relationships of age, visceral adiposity, insulin-like growth factor (IGF)-I and IGF binding protein concentrations to growth hormone (GH) releasing-hormone and GH releasing-peptide efficacies in men during experimental hypogonadal clamp.

Veldhuis JD, Keenan DM, Bailey JN, Adeniji AM, Miles JM, Bowers CY

The Journal of clinical endocrinology and metabolism7 Apr 2009Cited by 9 (Europe PMC)

PMID19351723 (opens in a new tab)PMCIDPMC2690428 (opens in a new tab)DOI10.1210/jc.2009-0136 (opens in a new tab)PepBankPUB-19351723
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    During testosterone and estradiol deprivation, older men had a 2-fold lower maximal GH response to GHRP‑2 than young men (P = 0.022).

    In plain wordsIn men with low sex hormones, older men had about half the peak GH response to GHRP‑2 of young men.

    Peptide
    GHRP-2
    Outcome
    DecreaseMaximal GH response to GHRP-2 in older versus young men
    Study

    n = 25

    Comparator
    Young men
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · infusionAs given in this study (human).

    Source sentences

    Summary
    During experimental testosterone/estradiol deprivation, older (57 +/- 1.7 yr) men maintained: 1) 6.8-fold less pulsatile GH secretion (P < 0.001); and 2) 2-fold lower maximal GH responses to GHRH (P = 0.0065) and GHRP-2 (P = 0.022) than young (23 +/- 1.1 yr old) individuals.
    2 context sentences
    Summary · context
    The study group included 13 healthy young men and 12 healthy older men.
    Summary · context
    We used GnRH agonist-induced down-regulation of testosterone and estradiol secretion, followed by consecutive infusion of l-arginine and GHRH or GHRP-2, to test secretagogue efficacies.
  2. 02HumanRandomized controlled trialMechanism

    In sex steroid-depleted men, abdominal visceral fat was a dominant negative predictor of GHRP‑2 efficacy (R2 = 0.38; P = 0.005).

    In plain wordsIn men with low sex hormones, more belly fat was linked to a weaker GH response to GHRP‑2.

    Peptide
    GHRP-2
    Outcome
    DecreaseAbdominal visceral fat as predictor of GHRP-2 efficacy
    Study

    n = 25

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · infusionAs given in this study (human).

    Source sentences

    Summary
    abdominal visceral fat as a dominant negative predictor of both GHRH (R(2) = 0.49; P = 0.001) and GHRP-2 (R(2) = 0.38; P = 0.005)
    2 context sentences
    Summary · context
    The study group included 13 healthy young men and 12 healthy older men.
    Summary · context
    We used GnRH agonist-induced down-regulation of testosterone and estradiol secretion, followed by consecutive infusion of l-arginine and GHRH or GHRP-2, to test secretagogue efficacies.
  3. 03HumanRandomized controlled trialMechanism

    In sex steroid-depleted men, fasting IGF-I was a major positive correlate of GHRP‑2 efficacy (R2 = 0.31; P = 0.018).

    In plain wordsIn men with low sex hormones, higher IGF-I was linked to a stronger GH response to GHRP‑2.

    Peptide
    GHRP-2
    Outcome
    IncreaseFasting IGF-I as correlate of GHRP-2 efficacy
    Study

    n = 25

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · infusionAs given in this study (human).

    Source sentences

    Summary
    fasting IGF-I concentration as a major positive correlate of GHRH (R(2) = 0.52; P < 0.001) and GHRP-2 (R(2) = 0.31; P = 0.018)
    2 context sentences
    Summary · context
    The study group included 13 healthy young men and 12 healthy older men.
    Summary · context
    We used GnRH agonist-induced down-regulation of testosterone and estradiol secretion, followed by consecutive infusion of l-arginine and GHRH or GHRP-2, to test secretagogue efficacies.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.